13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002018299
Total reported value
$1.3B
$1.3B
54 檔
28.7%
In Q1 2026, Boxer Capital Management, LLC's U.S. equity holdings reached a combined market value of $1.3B, distributed across 54 disclosed stock positions.
In Q1 2026, Boxer Capital Management, LLC displayed an active expansion posture, initiating 13 new positions and adding to 13 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | Stock-Other | 29.87% | -4.26% | — | |
| 2 | KOD | Kodiak Sciences Inc | Stock-Other | 6.81% | -2.47% | +19.81% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.38% | +0.67% | +25.00% | |
| 4 | KYMR | Kymera Therapeutics Inc | Stock-Other | 3.60% | +0.11% | — | |
| 5 | CELC | Celcuity Inc | Stock-Other | 3.37% | -0.09% | — | |
| 6 | SRZN | Surrozen Inc | Stock-Other | 2.93% | -0.90% | +84.14% | |
| 7 | ABVX | Abivax Sa-adr | Stock-Other | 2.92% | +3.15% | +60.00% | |
| 8 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.60% | -2.60% | EXIT | |
| 9 | PCVX | Vaxcyte Inc | Stock-Other | 2.48% | -1.06% | — | |
| 10 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.35% | +0.18% | +81.54% | |
| 11 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.35% | -0.78% | — | |
| 12 | VIR | Vir Biotechnology Inc | Stock-Other | 2.20% | -0.77% | +198.56% | |
| 13 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 2.11% | -0.87% | — | |
| 14 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.97% | -0.80% | — | |
| 15 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 1.79% | -0.56% | — | |
| 16 | PGEN | Precigen Inc | Stock-Other | 1.78% | +0.43% | +154.55% | |
| 17 | DFTX | Definium Therapeutics Inc | Stock-Other | 1.49% | +2.05% | — | |
| 18 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.46% | -0.38% | — | |
| 19 | QURE | uniQure N.V. | Stock-Other | 1.42% | +3.79% | +128.28% | |
| 20 | IRD | Opus Genetics Inc | Stock-Other | 1.34% | -0.47% | — | |
| 21 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 1.32% | +0.88% | — | |
| 22 | URGN | UroGen Pharma Ltd. | Stock-Other | 1.18% | +0.21% | — | |
| 23 | REPL | Replimune Group Inc | Stock-Other | 1.18% | +2.14% | +56.67% | |
| 24 | COGT | Cogent Biosciences Inc | Stock-Other | 1.14% | -0.48% | — | |
| 25 | PALI | Palisade Bio Inc | Stock-Other | 1.10% | -0.34% | — | |
| 26 | ✓ | Crescent Biopharma Inc. | Stock-Other | 1.09% | -0.47% | — | |
| 27 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.88% | -0.88% | EXIT | |
| 28 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.87% | -0.63% | — | |
| 29 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.87% | -0.23% | — | |
| 30 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.85% | -0.24% | — | |
| 31 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.77% | -0.07% | — | |
| 32 | RLMD | Relmada Therapeutics Inc | Stock-Other | 0.77% | -0.33% | — | |
| 33 | ✓ | Zura Bio LTD | Stock-Other | 0.70% | -0.30% | +1700.00% | |
| 34 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.67% | -0.27% | — | |
| 35 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.59% | -0.07% | +9.09% | |
| 36 | INO | Inovio Pharmaceuticals Inc | Stock-Other | 0.54% | -0.30% | -2.07% | |
| 37 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.47% | -0.17% | — | |
| 38 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.43% | -0.23% | — | |
| 39 | HELP | Cybin Inc | Stock-Other | 0.40% | -0.01% | -10.49% | |
| 40 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.39% | +0.57% | — | |
| 41 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.34% | -0.07% | — | |
| 42 | CLNN | Clene Inc | Stock-Other | 0.31% | -0.09% | +139.07% | |
| 43 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.29% | — | — | |
| 44 | SLDB | Solid Biosciences Inc | Stock-Other | 0.28% | -0.05% | — | |
| 45 | IVVD | Invivyd Inc | Stock-Other | 0.26% | -0.16% | — | |
| 46 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.23% | -0.06% | — | |
| 47 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.22% | — | +19.80% | |
| 48 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.20% | -0.02% | — | |
| 49 | UPB | Upstream Bio Inc | Stock-Other | 0.18% | -0.10% | — | |
| 50 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.10% | -0.03% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | TNGX | Tango Therapeutics Inc | +8.8% | — | Unchanged |
| 2 | VIR | Vir Biotechnology Inc | +1.4% | +198.56% | Add |
| 3 | SRZN | Surrozen Inc | +0.9% | +84.14% | Add |
| 4 | ✓ | Zura Bio LTD | +0.6% | +1700.00% | Add |
| 5 | PGEN | Precigen Inc | +0.5% | +154.55% | Add |
| 6 | CAPR | Capricor Therapeutics Inc | +0.3% | +81.54% | Add |
| 7 | CLNN | Clene Inc | +0.1% | +139.07% | Add |
| 8 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 9 | 4XC1 | Kalvista Pharmaceuticals Inc | 0% | — | Unchanged |
| 10 | SLDB | Solid Biosciences Inc | -0.1% | — | Unchanged |
| 11 | QURE | uniQure N.V. | -0.1% | +128.28% | Add |
| 12 | LBRX | Lb Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 13 | MLTX | Moonlake Immunotherapeutics | -0.1% | — | Unchanged |
| 14 | KOD | Kodiak Sciences Inc | -0.1% | +19.81% | Add |
| 15 | MIST | Milestone Pharmaceuticals In | -0.2% | — | Unchanged |
| 16 | KPTI | Karyopharm Therapeutics Inc | -0.2% | +19.80% | Add |
| 17 | NRIX | Nurix Therapeutics Inc | -0.2% | — | Unchanged |
| 18 | SRPT | Sarepta Therapeutics Inc | -0.3% | — | Unchanged |
| 19 | INO | Inovio Pharmaceuticals Inc | -0.4% | -2.07% | Trim |
| 20 | CTNM | Contineum Therapeutics Inc-a | -0.4% | — | Unchanged |
| 21 | APGE | Apogee Therapeutics Inc | -0.4% | — | Unchanged |
| 22 | REPL | Replimune Group Inc | -0.4% | +56.67% | Add |
| 23 | PEPG | Pepgen Inc | -0.5% | -27.01% | Trim |
| 24 | AVTX | Avalo Therapeutics Inc | -0.5% | +9.09% | Add |
| 25 | CYTK | Cytokinetics Inc | -0.5% | — | Unchanged |
| 26 | IVVD | Invivyd Inc | -0.6% | — | Unchanged |
| 27 | RVMD | Revolution Medicines Inc | -0.6% | +25.00% | Add |
| 28 | COGT | Cogent Biosciences Inc | -0.6% | — | Unchanged |
| 29 | AMLX | Amylyx Pharmaceuticals Inc | -0.7% | — | Unchanged |
| 30 | GPCR | Structure Therapeutics Inc | -0.7% | — | Unchanged |
| 31 | UPB | Upstream Bio Inc | -0.7% | — | Unchanged |
| 32 | 430 | Terns Pharmaceuticals Inc | -0.7% | — | Unchanged |
| 33 | ABVX | Abivax Sa-adr | -0.8% | +60.00% | Add |
| 34 | HELP | Cybin Inc | -0.9% | -10.49% | Trim |
| 35 | PTGX | Protagonist Therapeutics Inc | -0.9% | — | Unchanged |
| 36 | PRAX | Praxis Precision Medicines I | -1% | — | Unchanged |
| 37 | PALI | Palisade Bio Inc | -1.4% | — | Unchanged |
| 38 | URGN | UroGen Pharma Ltd. | -1.4% | — | Unchanged |
| 39 | CELC | Celcuity Inc | -1.5% | — | Unchanged |
| 40 | PTCT | Ptc Therapeutics Inc | -1.5% | — | Unchanged |
| 41 | KYMR | Kymera Therapeutics Inc | -2% | — | Unchanged |
| 42 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 43 | CRVS | Corvus Pharmaceuticals Inc | — | NEW | New buy |
| 44 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 45 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 46 | IRD | Opus Genetics Inc | — | NEW | New buy |
| 47 | CORT | Corcept Therapeutics Inc | — | NEW | New buy |
| 48 | ✓ | Crescent Biopharma Inc. | — | NEW | New buy |
| 49 | BRD1EUR | Mind Medicine Mindmed Inc | — | EXIT | Sold out |
| 50 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Boxer Capital Management, LLC reported a total U.S. public equity portfolio value of $1.3B across 54 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TNGX, KOD, RVMD) accounted for 28.7% of total reported equity market value during Q1 2026.
Top New Position Initiated
PCVX
市值: $18.9M
Top Position Liquidated / Trimmed
CDTX
前期市值: $11.7M
During Q1 2026, Boxer Capital Management, LLC's top holdings by market value included TNGX (29.9%)、KOD (6.8%)、RVMD (6.4%). The largest single position, TNGX, represented 29.9% of total portfolio value.
In Q1 2026, Boxer Capital Management, LLC made 33 total portfolio adjustments, initiating 13 new buys, adding to 13 positions, trimming 3 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.